A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Enrolling By Invitation. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 2
- Study design
- NON RANDOMIZED · SINGLE GROUP · TREATMENT · NONE
- Evidence population
- Human clinical study registration
- Participants
- 865
- Population
- ALL · 50 Years
- Duration
- 2019-05-31 to 2028-12-01
- Intervention
- RGX-314
- Comparator
- Main Observational Study
- Outcomes measured
- Incidence of ocular adverse events and any serious adverse events in the study eye — 5 years inclusive of parent study; Fellow eye substudy: Incidence of ocular adverse events and any serious adverse events in the fellow eye — 54 weeks; Change from baseline in best corrected visual acuity (BCVA) in the study eye — 5 years inclusive of parent study; Change from baseline in Central Retinal Thickness (CRT) in the study eye — 5 years inclusive of parent study; Number of supplemental anti-VEGF injections in the study eye — 5 years inclusive of parent study; Number of retinal specialist visits for the study eye — 5 years inclusive of parent study; Fellow eye substudy: Change from baseline in best corrected visual acuity — 54 weeks; Fellow eye substudy: Change from baseline in Central Retinal Thickness in the fellow eye — 54 weeks; Fellow eye substudy: Number of supplemental anti-VEGF injections in the fellow eye — 54 weeks; Fellow eye substudy: Aqueous and Serum RGX-314 transgene product (TP) concentrations in the fellow eye — 54 weeks; Fellow eye substudy: Immunogenicity measurements in the fellow eye — 54 weeks
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 60% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 60%Source terminology contains: age-related macular degeneration. Source terminology supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 65%. These figures help sort records; they are not medical ratings.